FINWIRES · TerminalLIVE
FINWIRES

Celestica Poised for Accelerated AI-Driven Growth in 2027, UBS Says

By

Celestica (CLS) is poised to see accelerated revenue and earnings per share growth in calendar year 2027, aided by strong AI-driven demand for Ethernet switching and AI/ML compute, UBS Securities said in a research note.

Building on this, UBS forecast a roughly 50% two-year EPS compounded annual growth rate to $24.72 in calendar year 2028 from $10.83 in 2026, according to the Sunday note.

UBS further said that scale-out and scale-up switch demand from Alphabet's (GOOGL, GOOG) Google and others should drive a 40% three-year CAGR in the company's communications revenue. Additionally, custom ASIC solutions by hyperscalers should drive enterprise revenue growth of about 127% in 2027 and a 52% CAGR over the next three years.

The investment firm lowered its EPS estimates for Celestica because of a previously announced equity offering and now expects Q3 EPS of $2.80 from $2.98. For 2026 and 2027, it lowered its estimates to $10.83 from $11.22 and $18.26 from $19.65, respectively.

UBS raised its rating to buy from neutral and its price target to $430 from $410.

Celestica shares were down 1% in Monday trading.

Price: $293.67, Change: $-2.88, Percent Change: -0.97%

Related Articles

Wire

Update: Regal Partners H1 Normalized Earnings, Revenue Up; Shares Fall 7%

(Updates to add stock movement in the headline and the last paragraph)Regal Partners (ASX:RPL) logged AU$0.214 in normalized EPS for the first half, compared with AU$0.105 a year ago, a Monday filing showed.For the six months ended June 30, income from ordinary activities was AU$226.4 million versus AU$128.7 million previously, the Australia-listed alternative investment manager company added.The board declared an interim dividend of AU$0.12 per share, up from AU$0.06 a year earlier, payable Sept. 30 to shareholders on record as of Aug. 31.The company's shares fell around 7% in recent Monday trade.

ASX:RPL
Wire

Philip Morris Reports FDA Authorization for ZYN ULTRA Nicotine Pouches

Philip Morris International (PM) said Friday it has obtained authorization from the US Food and Drug Administration for the marketing of 11 ZYN ULTRA moist oral nicotine pouch products.The firm said the FDA issued Marketing Granted Orders to its US affiliate, Swedish Match USA. Additional 11mg variants are still under scientific review, it added.The authorizations add selection of ZYN ULTRA products to its portfolio of alternatives for adults who smoke or use traditional oral tobacco products, the company said.Price: $188.44, Change: $-3.08, Percent Change: -1.61%

$PM
Wire

Top Cryptocurrencies Jump; Bitcoin Tops $77,000

Major digital assets jumped Friday, with Bitcoin (BTC-USD) topping $77,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 6.4% in the past 24 hours. The Nasdaq 100 and the S&P 500 each gained 0.5%, and the Dow Jones Industrial Average increased 0.8.%.Bitcoin gained 6.1% to $77,122, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume rose 16% to $71.1 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, rose 3.6% to $2,414.XRP (XRP-USD) surged 11%, BNB (BNB-USD) increased 3.7%, and Solana (SOL-USD) added 4%. Dogecoin (DOGE-USD) rose 5.7%, while Cardano (ADA-USD) jumped 11%.The total market value of the cryptocurrency industry rose 5.1% in the past 24 hours to $2.59 trillion, with trading volume gaining 9.2% to $161.4 billion.Price: $77126.61, Change: $+4113.61, Percent Change: +5.63%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD